Sim-12

Quick links to important sections

Sim-12

Method of action: Antianemic

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sim-12

Quick Facts

Property Description
Active Ingredient Cobamamide (Adenosylcobalamin)
Form Injection Solution and Oral Forms (tablets, capsules)
Pharmacological Class Antianemic Preparation / Metabolic Agent
General Purpose Supports Red Blood Cell Production and Nerve Health
Origin Synthetic Analogue of an Endogenous Metabolite

Sim-12: Definition and Pharmacological Class

Sim-12 is classified pharmacologically as an Antianemic Preparation and is functionally categorized as an essential Metabolic Agent. Its single active ingredient is Cobamamide, which is recognized scientifically as Adenosylcobalamin, the coenzyme form of Vitamin B12 required by human physiology.

This agent is clinically recognized for its direct role in cellular function, differentiating it from precursor compounds, such as Cyanocobalamin, that require metabolic conversion. Cobamamide belongs to the class of B12 analogues and is supplied as the endogenous metabolite—the specific structure naturally needed within the mitochondria for crucial biochemical reactions. This coenzymatic status is a key differentiating factor in its use.

What is Cobamamide and its Pharmaceutical Forms?

Cobamamide is the specific corrinoid structure that acts as a cofactor for key enzymes involved in energy and cellular division pathways. Sim-12 is manufactured as a synthetic analogue of this natural metabolite and is supplied as a Single Active Ingredient Product. The medicine is available in primary high-level dosage forms, including an Injection Solution presented in ampoules for parenteral administration, and various Oral Forms, such as tablets or capsules, for oral intake.

All preparations are designed to deliver the active Adenosylcobalamin molecule. This active form is essential for mitochondrial function and the biosynthesis of succinyl coenzyme A. This indicates the drug's role as a foundational support agent for critical energy processes within the body.

The Core Purpose of Sim-12 as an Essential B12 Agent

The fundamental general purpose of Sim-12 is to sustain vital metabolic and cellular processes, particularly those related to the nervous and hematopoietic systems. The Cobamamide coenzyme is indispensable for the proper synthesis of DNA, which is required for the continuous, healthy maturation of red blood cells. Furthermore, Cobamamide facilitates metabolic pathways necessary for maintaining the integrity of the myelin sheath, the protective layer surrounding nerve cells. Supplying this active coenzyme is crucial for maintaining stable blood formation and neurological function, which is the general therapeutic goal of this agent.

What side effects are possible with Sim-12?

Possible side effects and safety information

The officially documented safety profile for Sim-12 (Cobamamide/Adenosylcobalamin), particularly when administered by injection, is structured around specific physiological systems and serious, clinically significant events. The regulatory classification of adverse reactions primarily includes effects grouped by System-Organ Class rather than using specific frequency terms (e.g., Common, Rare).

Serious Adverse Reactions

Adverse reactions classified as serious in regulatory documents include anaphylactic shock and, rarely, death. Other clinically important events reported include pulmonary edema, congestive heart failure, and peripheral vascular thrombosis.

System-Organ Class (SOC) Grouped Reactions

System Class Officially Documented Adverse Reactions
Dermatological Itching (pruritus), transitory exanthema (rash)
Gastrointestinal Mild transient diarrhea
Cardiovascular Vascular thrombosis, edema, heart failure
Hematological Polycythemia vera

Time-Related and Population-Specific Safety

The regulatory label notes that certain cardiovascular events, such as pulmonary edema or congestive heart failure, have been reported early in treatment for megaloblastic anemia. Safety considerations exist for specific groups:

  • Leber's Disease: The medicine is restricted in patients with early hereditary optic nerve atrophy (Leber's disease).
  • Infants: Some parenteral formulations contain Benzyl Alcohol, which poses a risk for infants and premature neonates.
  • Renal Impairment: There is a documented risk of aluminum accumulation in patients with impaired kidney function using certain parenteral products.

The medicine is also restricted in individuals with known sensitivity to Cobalt or Vitamin B12.

Overdose and Emergency Response

Overdose and when to seek help

Cobamamide (Adenosylcobalamin), the active ingredient in Sim-12, has a low intrinsic toxicity profile. Due to its nature as a water-soluble coenzyme, official regulatory prescribing information generally states that no specific clinical manifestations of overdose are known. Any excess active substance that is not utilized by the body is typically managed through rapid renal excretion. This lack of documented systemic toxicity means that official regulatory labels do not list specific severe or life-threatening outcomes resulting directly from acute overexposure.

Despite this low toxicity documented in official sources, immediate medical attention must be sought for any suspected Sim-12 overdose event. This urgent action is required regardless of whether specific clinical signs are present. Furthermore, if any unexpected or severe symptoms are observed, contact with emergency services is mandated by regulatory guidance.

Overdose management, as described in official documents, is limited to general symptomatic and supportive treatment, as regulatory bodies confirm that no specific antidote is known for Cobamamide. Hospital monitoring may be required for observation, particularly following suspected overexposure from injectable or excessively large oral doses, ensuring appropriate clinical oversight as defined by the authorities.

Therapeutic Uses of Sim-12

What Sim-12 Treats: Main Uses and Benefits

The therapeutic use of Sim-12 (Cobamamide/Adenosylcobalamin) is generally focused on addressing the physiological imbalances that arise from a pronounced B12 deficiency. Accordingly, the agent is used to help with multiple symptomatic domains.

Sim-12 is applicable within clinical settings that involve acute or disruptive symptom patterns, including the management of Megaloblastic Anemia, related hematological disorders like Pernicious Anemia, and deficiency-linked peripheral neuropathy. It is also relevant for easing symptoms that create noticeable physiological strain, such as profound fatigue, generalized weakness, and uncomfortable sensory disturbances like tingling and numbness.

“The support provided assists with maintaining functional stability and helps improve day-to-day comfort during symptomatic periods.”

This medication is also commonly used to help with cognitive symptoms related to systemic imbalance, including memory loss or mental fog, and in the management of specific inherited metabolic disorders. The overall benefit provided helps ease the overall symptom burden and supports patients during episodes of heightened discomfort.


Quick Fact: Managing Symptoms: Fatigue and Numbness Description
Symptom Type Systemic and Neurological
Conditions Megaloblastic Anemia, Peripheral Neuropathy
Patient Benefit Supports maintenance of functional stability and physical vitality

Eligibility and Restrictions for Use

Who Can and Cannot Use Sim-12?

Sim-12 (Cobamamide) eligibility is defined by official regulatory documentation, primarily centered on absolute contraindications and diagnostic certainty.


Absolute Contraindications

Sim-12 must not be used by individuals with a known hypersensitivity to Cobamamide, other Vitamin B12 forms, or the element Cobalt. It is also contraindicated for patients with hereditary optic nerve atrophy (Leber's Disease), due to the regulatory warning that Cobalamins can accelerate nerve damage in this condition.


Restricted and Conditional Use

The medicine must not be used if megaloblastic anemia is solely due to folic acid deficiency. Use is restricted and conditional until a B12 deficiency is formally confirmed. This regulatory requirement prevents the medicine from masking the true cause of the anemia, which could otherwise allow neurological harm to progress.


Established Populations

Use of Sim-12 is established in adults, older adults, and pediatric patients when a B12 deficiency is confirmed. Therapeutic use is generally permitted during both pregnancy and lactation to treat documented maternal deficiency, consistent with the nutrient's essential status.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Sim-12 (Cobamamide) primarily focuses on substances that interfere with the absorption or assessment of Vitamin B12 status. No formal drug-drug contraindications involving Sim-12 as the sole active ingredient are explicitly documented in regulatory sources.

Substances Modifying Exposure or Absorption (Object Interactions)

Co-administration of certain medicinal products is officially documented to result in the malabsorption of Vitamin B12, which ultimately reduces the effective exposure to Cobamamide. These agents include Colchicine and Para-aminosalicylic acid (PAS). Separately, long-term use of gastric acid inhibitors, such as H2-receptor antagonists or Proton Pump Inhibitors, is associated with decreased B12 absorption, as is prolonged treatment with Metformin. Additionally, regulatory documents state that heavy alcohol intake lasting longer than two weeks may also result in B12 malabsorption.

Diagnostic and Pharmacodynamic Interference

Specific interactions are documented where co-administered substances can complicate the assessment of B12 deficiency. Folic acid at doses greater than 0.1 mg/day may produce hematologic remission, officially masking the true underlying B12 deficiency. Furthermore, certain substances, including antibiotics, Methotrexate, and Pyrimethamine, are officially listed as agents that can invalidate B12 diagnostic blood assays.

Population-Specific Formulation Note

For the parenteral (injection) formulation, a regulatory note advises caution in patients with impaired kidney function due to the potential for aluminum accumulation from product components upon prolonged administration.

Mechanism of Action

Gene Silencing: Controlling Production at the Source

This section outlines how Sim-12 works at the molecular level by targeting the genetic instructions. Sim-12 employs the body's natural RNA interference (RNAi) pathway to specifically degrade the messenger RNA (mRNA) that codes for the target Protein X. This precise action prevents the protein from being synthesized, resulting in a sustained reduction in the concentration of the specific protein.


The RISC-Mediated Mechanistic Cascade

This block details the cellular process through which the drug achieves its effect. Sim-12 integrates into the RNA-Induced Silencing Complex (RISC), which then acts as a guided molecular scissor to specifically cleave the target mRNA. This cascade ensures a highly targeted interaction, leading to post-transcriptional gene silencing that contributes to the adjustment of cellular regulation by modulating the downstream effects of Protein X activity.

Dosage and Administration Information

How Sim-12 (Cobamamide) is Used in Clinical Practice

Sim-12 (Cobamamide, or Adenosylcobalamin) is administered according to standardized protocols for B12 replacement therapy, with the choice of route and dose determined by the severity of the deficiency and the patient's ability to absorb the vitamin.


Official Routes and Forms

Sim-12 is available as an Injection Solution for parenteral use and in various Oral Forms (tablets or capsules).

  • Parenteral Routes: The injection solution is administered via Intramuscular (IM) or Deep Subcutaneous (SC) routes. This method is typically mandatory for the initial correction phase in patients with severe deficiency or known malabsorption.
  • Oral Route: High-dose oral forms (e.g., 1000 mu g to 2000 mu g) are used for chronic maintenance, as sufficient absorption occurs through passive diffusion, bypassing the need for intrinsic factor.

Standard Dosage Regimens

Usage follows a two-phase dosing regimen for adult patients, consistent with standard clinical protocols:

Regimen Phase Dose Frequency / Pattern
Initial/Correction (Parenteral) 1000 mu g (1 mg) Daily for approximately seven days, or three times a week for two weeks, to establish body stores.
Maintenance (Parenteral) 1000 mu g (1 mg) Monthly or every 2–3 months for life in cases of permanent malabsorption.
Maintenance (Oral) 1000 mu g to 2000 mu g Once Daily for chronic replacement therapy.

Administration Context and Duration

  • Duration of Use: For conditions like pernicious anemia, treatment is typically required for life. For temporary causes of deficiency, treatment continues until blood counts and biochemical parameters normalize.
  • Procedural Constraint: Official labels stipulate a specific constraint regarding co-administration: Sim-12 treatment must precede or occur concurrently with folic acid administration to comply with safety protocols. The oral form may be taken independent of or before food, depending on the specific formulation.
  • Pediatric Use: Established clinical guidelines specify different, lower daily doses for pediatric patients with nutritional deficiency, often in the microgram range (0.5 mu g to 3 mu g).

Recent Clinical Evidence

Research evidence / Overview of studies for Sim-12 (Cobamamide)

This overview summarizes the available research regarding Sim-12 (Cobamamide/Adenosylcobalamin), focusing strictly on the types of studies conducted, the outcomes they measured, and what remains uncertain in the evidence landscape, as reported in authoritative governmental and peer-reviewed sources.

Evidence for Use in Megaloblastic Anemia

The largest volume of research for Sim-12 and related active B12 forms exists for conditions involving Megaloblastic Anemia. The primary evidence in this area comes from Randomized Controlled Trials (RCTs) and systematic reviews applied in studies examining adult populations with confirmed B12 deficiency. These trials monitored changes in key hematological parameters, such as Red Blood Cell maturation and levels of hemoglobin, over defined time intervals. Findings describe patterns related to measurable changes in these blood measures. Historical research on B12 deficiency often included other forms of the vitamin, and the specific long-term findings related to Cobamamide in diverse patient groups remain limited.

Research on Neurological Function and Peripheral Neuropathy

Sim-12 was studied for use in addressing deficiency-linked peripheral neuropathy, which often involves uncomfortable sensory disturbances like tingling and numbness. Evidence for this domain is drawn from a mixture of RCTs, observational cohorts, and smaller, symptom-focused clinical trials. Research examined outcomes related to physical discomfort by using specific neurological function scores and by measuring sensory and motor nerve conduction velocity. Because these studies involve outcomes related to physical discomfort that can vary in intensity, the reported findings were mixed, and certainty remains low to moderate compared to the findings for hematological parameters.

Evidence in Special Populations and Research Gaps

Research has explored certain cohorts, such as children with inherited disorders and, in some cases, older adults presenting with neurological or functional limitations. However, data for certain groups remain insufficient. Long-term comparative evidence that directly contrasts the sustained clinical patterns of Cobamamide against other B12 forms over many years is generally lacking in the current research landscape, as noted by regulatory summaries. Existing studies provide limited insight into how any potential differences translate into a sustained clinical advantage in patient-reported outcomes describing perceived discomfort or daily functioning over a lifetime.

Frequently Asked Questions (FAQ)

Common questions about Sim-12 (FAQ)


Q: Is it common to feel tired after starting Sim-12?

Official regulatory documentation that describes the safety profile for B12 agents, including related forms of Sim-12, does not typically list fatigue or tiredness as a commonly documented side effect under the System-Organ Classifications. Side effect lists usually focus on reactions with a clearer link to the drug’s intended use or route of administration.


Q: What should be done if a potential drug interaction is discovered?

Official patient and professional guidelines indicate that all suspected interactions, or the possibility of an interaction, is best addressed through discussion with a healthcare professional who is managing your care. Additionally, serious or unexpected reactions and interactions can be reported to the official regulatory body in your country for assessment and documentation.


Q: What kind of monitoring is usually recommended when using Sim-12?

Regulatory-backed clinical surveillance for B12 deficiency treatment generally involves regular laboratory tests to assess the body's response. This monitoring typically checks hematological parameters (your blood counts) and specific biochemical markers (like methylmalonic acid and homocysteine) at defined intervals to help ensure the therapy is achieving its goals.


Q: Is it possible for Sim-12 to cause an allergic reaction?

Yes, it is possible. Official documents list anaphylactic shock as a serious adverse reaction and state that the medicine is contraindicated (must not be used) in people with a known hypersensitivity to Cobamamide, other B12 forms, or the element Cobalt. This restriction is in place to help prevent severe allergic responses.


Q: Is Sim-12 suitable for vegetarians or people with common allergies?

Sim-12 (Cobamamide) is a synthetic analogue of a B12 metabolite. Official sources state that B12 is not naturally found in plant-based diets, which is why this treatment may be relevant for some vegetarians. Official labels detail specific warnings for known sensitivity to Cobalt or B12 itself, but they do not typically address general common allergies outside of those specific contraindications.


Q: Why might a doctor switch a patient from an old medicine to Sim-12?

Regulatory definitions of Sim-12 (Cobamamide) highlight that it is supplied as the active Adenosylcobalamin coenzyme form of B12. This structure is the endogenous metabolite, meaning it is the specific B12 structure naturally required by the body's cells for crucial energy and biochemical reactions. This specific coenzymatic status differentiates it from precursor forms like Cyanocobalamin.


Q: What is the difference between Sim-12 and a supplement with similar claims?

Sim-12 is a single-active-ingredient prescription medicine (Cobamamide) that is strictly regulated for specific B12 deficiency conditions. Supplements are regulated differently than prescription drugs and may contain various forms of B12 and other non-regulated ingredients. The primary distinction is their regulatory class and the stringent evidence required for prescription use.


Q: Are there specific warnings about Sim-12 in patients with heart conditions?

Official documentation notes that serious cardiovascular events, including pulmonary edema (fluid in the lungs) and congestive heart failure, have been reported as adverse reactions, sometimes early in the treatment phase for megaloblastic anemia. The label also lists vascular thrombosis (blood clots) as a reported adverse reaction.


Q: What information is available about Sim-12 and its effects on vision?

Sim-12 is strictly contraindicated (must not be used) in patients with hereditary optic nerve atrophy (Leber's Disease). Regulatory warnings indicate that B12 agents can accelerate nerve damage in this specific, rare condition. There is no generalized warning or documentation regarding effects on vision for the broader patient population.


Q: Does Sim-12 have any known impact on fertility?

Regulatory reviews for drugs like Sim-12 address potential effects on fertility. Based on the official product information for B12 agents, including those containing Cobamamide, there is generally no data or no known adverse effect on fertility.


Q: Can Sim-12 cause headaches?

Official regulatory lists of adverse events for B12 agents do not typically list headache in their core System-Organ Class sections. However, general safety summaries for the vitamin form may mention headache as a possible mild and transient effect.


Q: Why is Sim-12 prescribed over other options?

Sim-12 is the active Adenosylcobalamin coenzyme form of B12. Regulatory definitions highlight that it is supplied as the endogenous metabolite, meaning it is the specific structure naturally required by the body's cells for crucial energy and biochemical reactions, differentiating it from precursor forms like Cyanocobalamin. This may be part of the rationale for its selection.


Q: How quickly does Sim-12 usually start to show an effect?

While the dosage regimen specifies a high-dose Correction Phase, such as daily use for approximately seven days, official documentation does not specify a precise timeline for when a patient may feel a noticeable change. Research primarily monitors the measurable change in hematological parameters (blood counts) over defined time intervals, which is an objective measure of the body’s initial response.


Q: What are the most common side effects listed for Sim-12?

Official safety documents list adverse reactions by the body system they affect, such as Dermatological (rash, itching) and Gastrointestinal (mild, transient diarrhea). However, the labels often do not categorize them using specific frequency terms like 'most common' or 'rare,' as they primarily group effects by System-Organ Class.


Q: What are some less common, but serious, side effects of Sim-12?

Official regulatory sources list several serious adverse reactions, which include anaphylactic shock and, rarely, death. Other clinically important events reported include pulmonary edema, congestive heart failure, and peripheral vascular thrombosis. These events are classified as serious and require immediate attention.


Q: Does Sim-12 cause weight changes?

Official regulatory safety documentation for Sim-12 does not list weight gain or loss as an officially documented adverse reaction under any of the System-Organ Class categories. The listed side effects focus on areas such as dermatological, gastrointestinal, and cardiovascular reactions.


Q: Can Sim-12 affect my sleep?

Official safety documentation for Sim-12 does not list specific sleep-related disturbances, such as insomnia or drowsiness, as officially documented adverse reactions under the System-Organ Classifications.


Q: Does Sim-12 affect blood pressure?

The official documentation lists serious Cardiovascular reactions, including vascular thrombosis, edema, and congestive heart failure. However, it does not explicitly list hypertension (high blood pressure) or hypotension (low blood pressure) as specific, separate adverse reactions.


Q: Do official sources describe Sim-12 as causing mood changes?

Official regulatory safety documentation for Sim-12 does not list mood changes or any other psychiatric/nervous system reactions under the System-Organ Classifications, apart from the strict restriction regarding Leber's Disease.


Q: Is it described as normal to have gastrointestinal side effects from Sim-12?

The official safety profile lists mild transient diarrhea as a documented gastrointestinal adverse reaction. While the occurrence is documented, the regulatory label does not use the term 'normal' or provide the specific frequency (e.g., 'common' or 'rare') to describe how often patients might experience this side effect.


Q: What is the general expectation for the effectiveness of Sim-12 over weeks?

The research evidence primarily monitors objective changes in hematological parameters (blood counts) over defined time intervals. However, official summaries do not provide a specified timeframe for a patient to notice a sustained clinical effect in perceived discomfort or daily functioning, as this can vary widely.


Q: What are the ingredients in Sim-12 besides the active substance?

Sim-12's single active ingredient is Cobamamide. Official safety documents mention the inactive ingredient Benzyl Alcohol as a component in certain parenteral (injection) formulations, which carries a specific safety warning for infants. The contraindication for patients sensitive to Cobalt also suggests the presence of related compounds in the product.

How should Sim-12 be stored and disposed of?

The storage and disposal of Sim-12 (Cobamamide) must adhere strictly to official regulatory guidelines to ensure stability and public safety.

Storage Requirements

Condition Regulatory Mandate
Temperature Store at Controlled Room Temperature (typically 20°C to 25°C), and do not expose to temperatures exceeding 30°C.
Protection Must be protected from light and moisture; keep the container tightly closed in the original packaging.
Handling The Injection Solution form is strictly required not to be frozen. Discard the product if visible discoloration or particles appear.
Child Safety Mandatory instruction: The medicine must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired Sim-12 must be disposed of according to local regulations.

  • General Rule: Do not throw the medication into the regular trash or dispose of it down a sink or toilet unless explicitly instructed by the official label.
  • Sharps: Used needles, syringes, and ampoules associated with the injection must be placed in an approved puncture-resistant sharps container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sim-12 found in:

A-Z Index: